Shukur L R, Powers J L, Marques R A, Winter M E, Sadée W
Clin Chem. 1977;23(4):636-8.
We measured procainamide (I) and its metabolite, N-acetylprocainamide (II), in human serum samples by solvent extraction, high-performance liquid chromatography on a reverse phase column, and detection at 280 nm, with use of external standards. The method requires 0.2 ml of serum and is sensitive to 0.3 mg of I and 0.6 mg of II per liter of serum, with intra-assay standard deviations of 0.22 and 0.24 mg/liter, respectively, at 5 mg/liter (N=10) and inter-assay standard deviations of 0.63 and 0.81 mg/liter, respectively, at 7.5 mg/liter (CV 8.4 and 10.5%, respectively, n = 20). Concentrations measured by high-performance liquid chromatography and by an established fluorescence technique correlated well (r = 0.98 for I and 0.97 for II). No interfering substances were found in 20 randomly selected sera from patients receiving a large number of other drugs. Of the pure drug substances tested only sulfathiazole interfered with the assay of II. The method is therefore suitable for routinely monitoring these compounds in serum in a clinical laboratory. The high concentrations of the metabolite in a significant number of patients demonstrate the need to consider it as well as the parent drug as guides in optimizing dosage regiments for I.
我们采用溶剂萃取、反相柱高效液相色谱法，并在280nm波长下使用外标进行检测，测定了人血清样本中的普鲁卡因酰胺（I）及其代谢产物N-乙酰普鲁卡因酰胺（II）。该方法需要0.2ml血清，对每升血清中0.3mg的I和0.6mg的II敏感，在5mg/L时（N = 10），批内标准差分别为0.22和0.24mg/L，在7.5mg/L时（n = 20），批间标准差分别为0.63和0.81mg/L（变异系数分别为8.4%和10.5%）。高效液相色谱法和既定荧光技术测得的浓度相关性良好（I的r = 0.98，II的r = 0.97）。在随机选取的20份接受大量其他药物治疗的患者血清中未发现干扰物质。在所测试的纯药物物质中，只有磺胺噻唑干扰II的测定。因此，该方法适用于临床实验室常规监测血清中的这些化合物。大量患者体内代谢产物的高浓度表明，在优化I的给药方案时，需要将其与母体药物一并作为指导因素加以考虑。
